Compared to other hypoglycemic GLP-1 analogs, injectable liraglutide marketed by Novo Nordisk has reiterated its position as an efficient and safe post prandial glycemic level controller. Here is the study.

Team@CMHF

This review updates the pharmacology, efficacy, safety, and tolerability of liraglutide, a glucagon-like peptide 1 (GLP-1) analog approved for the treatment of type 2 diabetes (T2DM) in January 2010.

A GLP-1 analog with pharmacokinetic properties allowing once-daily administration via subcutaneous injection, liraglutide has shown clinical benefits when used as monotherapy or in combination. Liraglutide has also been studied in combination with metformin, glimepiride, and rosiglitazone for the treatment of T2DM. Extension studies within the Liraglutide Effects and Action in Diabetes clinical program have demonstrated the efficacy of liraglutide over 2 years of treatment.

Overall, liraglutide has been shown to be well tolerated, with dose-dependent nausea, vomiting, and diarrhea being the most commonly reported adverse events in clinical trials. Extended dosing periods have demonstrated the durability of response of liraglutide with respect to glycemic control, lack of weight gain, and blood pressure benefits. Compared with exenatide and sitagliptin, liraglutide seems to offer greater improvements in A1C, fasting plasma glucose, and body weight.

Emerging data suggest that liraglutide may be a useful option for patients with T2DM

Ref:  http://www.docguide.com/liraglutide-treatment-type-2-diabetes-clinical-update?hash=80445d1a&eid=21094&alrhash=2efbb8-880279c42369cc2f8adcb48a6daaf3d2